Answers are grounded in this paper and cite their sources.
The ability to rapidly create complex, multimaterial structures affordably and with minimal waste has established three-dimensional (3D) printing as a valuable tool for biosensor manufacturing. However, despite substantial progress in developing 3D-printed biosensors, their translation into clinical use remains limited. In this Opinion, we discuss the major barriers to widespread deployment of these technologies, including reliance on manual post-printing processing, limited manufacturing reproducibility, instability of biological recognition elements, insufficient validation under realistic operating conditions, and regulatory challenges. We highlight emerging solutions, including multifunctional printable materials, automated fabrication workflows, laser-induced surface modification, and hybrid manufacturing approaches, that may enable scalable and reproducible device fabrication. Finally, we propose directions for analytical validation, standardization, and regulatory readiness, providing a framework to accelerate the transition of 3D-printed biosensors from laboratory prototypes to real-world applications.
No takes yet. Share an insight, caveat, or question.
Veloso et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: